Goodness Growth Holdings Past Earnings Performance
Past criteria checks 0/6
Goodness Growth Holdings's earnings have been declining at an average annual rate of -1.3%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 25% per year.
Key information
-1.3%
Earnings growth rate
28.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 25.0% |
| Return on equity | n/a |
| Net Margin | -25.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Goodness Growth Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 93 | -24 | 31 | 0 |
| 31 Dec 23 | 88 | -26 | 32 | 0 |
| 30 Sep 23 | 83 | -34 | 33 | 0 |
| 30 Jun 23 | 77 | -37 | 36 | 0 |
| 31 Mar 23 | 78 | -36 | 35 | 0 |
| 31 Dec 22 | 75 | -42 | 37 | 0 |
| 30 Sep 22 | 69 | -43 | 39 | 0 |
| 30 Jun 22 | 64 | -41 | 39 | 0 |
| 31 Mar 22 | 57 | -41 | 39 | 0 |
| 31 Dec 21 | 54 | -34 | 39 | 0 |
| 30 Sep 21 | 53 | -22 | 36 | 0 |
| 30 Jun 21 | 52 | -13 | 34 | 0 |
| 31 Mar 21 | 50 | -22 | 40 | 0 |
| 31 Dec 20 | 49 | -23 | 39 | 0 |
| 30 Sep 20 | 48 | -63 | 44 | 0 |
| 30 Jun 20 | 42 | -78 | 45 | 0 |
| 31 Mar 20 | 36 | -62 | 35 | 0 |
| 31 Dec 19 | 30 | -57 | 28 | 0 |
| 30 Sep 19 | 25 | -17 | 20 | 0 |
| 30 Jun 19 | 22 | -4 | 15 | 0 |
| 31 Mar 19 | 21 | -4 | 12 | 0 |
| 31 Dec 18 | 18 | -3 | 12 | 0 |
| 30 Sep 18 | 16 | -2 | 9 | 0 |
| 31 Dec 17 | 11 | 0 | 6 | 0 |
| 31 Dec 16 | 4 | 6 | 4 | 0 |
Quality Earnings: 0ZF0 is currently unprofitable.
Growing Profit Margin: 0ZF0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0ZF0 is unprofitable, and losses have increased over the past 5 years at a rate of 1.3% per year.
Accelerating Growth: Unable to compare 0ZF0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0ZF0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).
Return on Equity
High ROE: 0ZF0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.